Radiotherapy in low grade gliomas benefit with local control advantage
Patients with high risk factors need immediate radiation after surgery
RT dose of 50-54 Gy in 2 Gy/Fr
Fractionated radiosurgery in optic nerve glioma and small volume disease
Aim of this ppt presentation:
To understand the standard of care for both GBM and anaplastic glioma.
To know what is the new advances and modifications to the standard of care?
Contents:
Introduction: 2 slides.
GBM:
Epidemiology: 1 slide.
Molecular biology & New trends: 5 slides
EORTC/NCIC trial: 10 slides.
MGMT: 1 slide.
Evidence-based medicine: 6 slides.
Avastin in GBM: 2 slides.
Novocure (TTF): 2 slides.
Gliadel (BCNU) wafers: 1 slide.
Anaplastic astrocytoma: 7 slides
Take home message.
General management
Management of low grade gliomas: overview
Pilocytic astrocytoma
non pilocytic/diffuse infiltrating gliomas
Management of high grade gliomas: overview
Anaplastic gliomas
Glioblastoma multiformae
Radiotherapy in low grade gliomas benefit with local control advantage
Patients with high risk factors need immediate radiation after surgery
RT dose of 50-54 Gy in 2 Gy/Fr
Fractionated radiosurgery in optic nerve glioma and small volume disease
Aim of this ppt presentation:
To understand the standard of care for both GBM and anaplastic glioma.
To know what is the new advances and modifications to the standard of care?
Contents:
Introduction: 2 slides.
GBM:
Epidemiology: 1 slide.
Molecular biology & New trends: 5 slides
EORTC/NCIC trial: 10 slides.
MGMT: 1 slide.
Evidence-based medicine: 6 slides.
Avastin in GBM: 2 slides.
Novocure (TTF): 2 slides.
Gliadel (BCNU) wafers: 1 slide.
Anaplastic astrocytoma: 7 slides
Take home message.
General management
Management of low grade gliomas: overview
Pilocytic astrocytoma
non pilocytic/diffuse infiltrating gliomas
Management of high grade gliomas: overview
Anaplastic gliomas
Glioblastoma multiformae
This is a PDF of a presentation given to the Radiation Oncology department at the University of Minnesota in October 2015. This PDF focuses on evaluation, management, and state-of-the-art approach to gliomas from a medical neuro-oncology perspective.
This is a PDF of a presentation given to the Radiation Oncology department at the University of Minnesota in October 2015. This PDF focuses on evaluation, management, and state-of-the-art approach to non-glioma tumors from a medical neuro-oncology perspective.
This is a PDF of a presentation given to the Radiation Oncology department at the University of Minnesota in October 2015. This PDF focuses on evaluation, management, and state-of-the-art approach to gliomas from a medical neuro-oncology perspective.
This is a PDF of a presentation given to the Radiation Oncology department at the University of Minnesota in October 2015. This PDF focuses on evaluation, management, and state-of-the-art approach to non-glioma tumors from a medical neuro-oncology perspective.
Iterative model.
Spiral model
RAD(Rapid application development)
model.
Iterative model.
Spiral model
RAD(Rapid application development)
model.
A Water Fall Model is easy to flow.
It can be implemented for any size of project.
Every stage has to be done separately at the right time so you cannot jump stages.
Documentation is produced at every stage of a waterfall model allowing people to understand what has been done.
Testing is done at every stage.
This model was not the first model to discuss iterative development.
As originally envisioned, the iterations were typically 6 months to 2 years long.
Each phase starts with a design goal and ends with the client (who may be internal) reviewing the progress thus far.
Analysis and engineering efforts are applied at each phase of the project, with an eye toward the end goal of the project.
This model was not the first model to discuss iterative development.
As originally envisioned, the iterations were typically 6 months to 2 years long.
Each phase starts with a design goal and ends with the client (who may be internal) reviewing the progress thus far.
Analysis and engineering efforts are applied at each phase of the project, with an eye toward the end goal of the project.
This model was not the first model to discuss iterative development.
As originally envisioned, the iterations were typically 6 months to 2 years long.
Each phase starts with a design goal and ends with the client (who may be internal) reviewing the progress thus far.
Analysis and engineering efforts are applied at each phase of the project, with an eye toward the end goal of the project.
This approach carries less risk than a traditional Waterfall approach but is still far more risky and less efficient than a more Agile approaches.
In Iterative model, iterative process starts with a simple implementation of a small set of the software requirements and iteratively enhances the evolving versions until the complete system is implemented and ready to be deployed.
Iterative model.
Spiral model
RAD(Rapid application development)
model.
The first formal description of the waterfall model is often cited as a 1970 article by Winston W. Royce
Royce did not use the term "waterfall" in this article.
Royce presented this model as an example of a flawed, non-working model.
Aim: to evaluate the effi cacy and tolerability of electro-hyperthermia (ET) for the treatment of relapsed malignant glioma.
Methods: this was a retrospective observational clinical study. Patients were included in the study if they had >18 years, informed consent signed, histological diagnosis of malignant glioma, failure of previous temozolamide-based chemotherapy and radiotherapy, indication for treatment with ET.
Hyperthermia was performed with short radiofrequency waves of 13.56 MHz using a capacitive coupling technique keeping the skin surface at 26 C°. The applied power ranged between 40-150 Watts and the calculated average equivalent temperature in the tumors was above 40 C° for more than 90% of the treatment duration (20-60 minutes gradually).
Adjuvant treatment in high risk endometrial carcinoma.pptxKomalMittal55
Molecular classification is an emerging topic in endometrial carcinoma… which has led to few updates in the risk stratification and treatment of endometrial carcinoma
The Role of Radiotherapy in the Treatment of Early Stage Ocular Marginal Zone...daranisaha
To evaluate the benefit of radiotherapy, compared with other treatment in ocular marginal zone lymphoma, retrospectively we analyzed our experience, with the end-points: efficacy, measured for complete response, Progression-Free Survival (PFS) and Overall Survival
Clinical Development of ADC Drugs Targeting TROP-2.pdfDoriaFang
TROP-2 is expressed in many tumor types, making it an emerging and popular target for ADC development. This article introduces clinical development of ADC drugs targeting TROP-2.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
Future direction in the management of high risk LOW GRADE GLIOMA
1. FUTURE DIRECTION IN THE MANAGEMENT OF
HIGH RISK LOW GRADE GLIOMA
JOURNAL CLUB
Dr. Joydeep Basu
Registrar
Apollo Gleneagles
Cancer Hospital
2. WHO CLASSIFICATION OF GLIOMA
Grade I – Pilocytic Astrocytoma
Grade II – Diffuse Fibrillary Astrocytoma,
Oligoastrocytoma , Oligodendroglioma
Grade III – Anaplastic Astrocytoma
Grade IV – Glioblastoma Multiformes
3. MANAGEMENT OF LOW GRADE GLIOMA
Maximal Safe Resection of the Tumour
Post operative Radiotherapy
CONTROVERSIES
a. Timing of Radiotherapy
b. Dose of Radiotherapy
c. Role and timing of Chemotherapy
4.
5. TIMING OF RADIOTHERAPY
EORTC 22845
314 patients with LGG were randomized to observation or post-
operative radiotherapy
Patients who were observed, received radiation on progression.
Dose – 54Gy/30Fr/6 weeks
Median PFS was 5.3 years in early RT arm vs 3.4 years in
observation arm (p <0.0001).
Seizure control was superior in early RT arm
Median survival (7.4 vs 7.2 years) & future malignant
transformation rate in both arms are similar
6.
7. DOSE OF RADIOTHERAPY
EORTC 22844
379 Patients were randomized to receive 45Gy in 5 weeks or
59.4Gy in 6.6 weeks.
Median follow up of 7.4 years
Overall Survival (56% vs 59%) & Progression free survival
(47% vs 50%) were similar in both groups.
8. DOSE OF RADIOTHERAPY CONTD.
Joint NCCTG, RTOG & ECOG study
203 patients were randomized to 50.4Gy in 28 Fr. or 64.8Gy in
36 Fr.
No difference in PFS & OS between both arms
Grade 3 &5 neurotoxicity occurred in 5% of patients in high
dose arm & 2.5% of patients in low dose arm.
Low dose radiotherapy is the standard of care for patients
with Low Grade Glioma.
9.
10. TRIAL DETAILS
RTOG 0424 is a single arm Phase II trial.
Survival data are compared with historical data.
43% (40.5 months to 57.9 months) increase in median survival
time & 20% (54% to 65%) increase in 3 year overall survival are
required for statistical significance.
11. TRIAL DETAILS CONTD.
Study was started in Jan. 2005
Amended in Feb. 2006 for post hoc determination of QOL,
neurological functional status evaluation & Methylguanine DNA
methyltransferase promoter methylation status.
Study was closed in Aug. 2009.
Total 136 patients entered the study of which 7 were excluded from
the final analysis.
So 129 HIGH RISK patients were available for the final analysis.
12. DEFINITION OF HIGH RISK LGG PATIENTS
Risk Factors
a) Age > 40 years
b) Largest pre-operative tumour diameter of >= 6 cm .
c) Tumour crossing corpus callosum.
d) Astrocytoma histology
e) Pre-operative neurological function deficit.
Patients with >= 3 risk factors are considered high risk patients.
13. ELIGIBILITY CRITERIA
Supratentorial WHO Grade II astrocytoma, oligoastrocytoma,
oligodendroglioma confirmed by central pathology review with
at least 3 risk factors.
Cancer free for at least 5 years
Must be enrolled < 12 weeks from surgery
Pre-treatment ECOG performance status of 0 to 2
Pre & post operative brain MRI with & without contrast were
required within 4 weeks of surgery.
15. TREATMENT
Maximal safe Resection
Radiation therapy by 3-D conformal radiation (3-D CRT) to a
dose of 54Gy/30 Fraction/6 weeks
Radiation volume – Post-operative T2 weighted MRI images of
residual tumour and/or surgical cavity plus a 2 cm margin is
used.
16. TREATMENT CONTD.
Concurrent oral Temozolamide (Dose - 75 mg/m2/day) was
given during radiation
Adjuvant oral Temozolamide (Dose – 150-200 mg/m2/day), Day
1-5, repeated every 28 days for upto 12 cycles.
Prophylaxis was given for P. carinii infection.
Dose modification done on basis of low blood count.
Drug stopped on progression or unacceptable toxicity.
17. FOLLOW UP
Evaluated monthly post radiation during adjuvant TMZ therapy.
After 4 month post – TMZ adjuvant therapy.
Every 6 months thereafter.
MRI brain was done 4 weeks post radiation & then every 3
months.
18.
19. 123 of 129 patients (95.3 %) received radiation
according to protocol.
Target volume received 90% - 110% of the prescribed
total dose of radiation.
98 of 129 patients (80%) received chemotherapy
according to protocol.
Median follow up for all patients and all surviving
patients were 4.1 years & 5.0 years respectively.
20. RESULTS
3 year OVERALL SURVIVAL is 73.1% which is significantly
higher than the historical data (p < 0.001).
Median PROGRESSION FREE SURVIVAL was 4.5 years.
3 year PROGRESSION FREE SURVIVAL was 59.2%.
Median survival time has not been reached.
Analysis of relation between OS & PFS with risk factors showed
that only histology is significantly associated with OS & PFS.
21.
22.
23. CRITICISM OF THE STUDY
Data are compared with historical data. Surgery, imaging,
radiation planning & treatment delivery have changed a lot over
time.
There was lack of central pathological review in historical
studies.
There is difference in timing of treatment intervention in Low
Grade Glioma patients in US & Europe. In Europe treatment is
delayed till tumour or symptom progression. It is not so in USA.
This leads to Lead Time Bias.
24. MOLECULAR SUBGROUP ANALYSIS
Patients with MGMT methylation has increased response to
Temozolamide.
1p19q codeletion, IDH mutation are associated with increased
response to Temozolamide.
Study was amended in Feb. 2006 and tissue samples are
collected for post hoc determination of MGMT methylation
status.
Molecular analysis of 1p19q codeletion, IDH mutation, PTEN
promoter methylation is underway and will be reported
separately.
25.
26.
27.
28. In order to fit the trial data to EORTC SURVIVAL CALCULATOR
a) tumor size had to be reclassified as <5 cm versus 5cm
(rather than <6 cm vs 6 cm)
b) 5 histopathological categories had to be reassigned to
2 categories (ie astrocytoma vs oligodendroglioma
and oligoastrocytoma [O/OA]).
According to the survival calculator there are 12 low risk cases.
Remaining 117 patients are intermediate & high risk patients.
Comparison with EORTC & RTOG/NCCTG trials show similar
survival in high risk group, & somewhat improvement in survival
in intermediate risk group.
29.
30.
31.
32. CONCLUSION
Initial results show that addition of chemotherapy to radiation
therapy for LGG patients has survival benefit.
Further molecular analysis is required for determining the
subgroup of patients who will benefit from addition of
chemotherapy the most.
Future efforts should also include neurocognitive assessment,
QOL, and development of surrogates for OS to allow for earlier
evaluation of results in this group of patients with prolonged
OS.